Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...

The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Morgan Stanley from $70.00 to $38.00 in a report ...

Research analysts at Leerink Partnrs cut their FY2024 earnings estimates for shares of Moderna in a note issued to investors ...

These are the recent developments in Madrigal Pharmaceuticals. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Continue reading in ...

Moderna MRNA provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At ...

Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...

J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...